Stock CALTX CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:42 2024-05-31 am EDT 		5-day change 1st Jan Change
208.2 SEK +0.10% Intraday chart for Calliditas Therapeutics AB +81.83% +63.81%
May. 31 Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 MT
May. 31 Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment MT

Evolution of the average Target Price on Calliditas Therapeutics AB

Price target over the last 5 years

History of analyst recommendation changes

2ad8f30e886f83767c.sSvNvq8_9YPzmItFutM8ahu4EaMmstplwWfl0ZpWJa8.9W-D7uNVgeqr0ukvy7V5OVKBXtlL15ddmDaBhcomSsb6E_z2-E6664qgyg~f92073011a85ae507f4bcb6269f6a806

Analyst Recommendations on Calliditas Therapeutics AB

Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 MT
HC Wainwright Downgrades Calliditas Therapeutics to Neutral From Buy, Cuts Price Target to $39 From $45 MT
Stifel Downgrades Calliditas Therapeutics to Hold From Buy, Cuts Price Target to $40 From $55 MT
HC Wainwright Cuts Calliditas Therapeutics Price Target to $45 From $50, Maintains Buy Rating MT
Guggenheim Adjusts Calliditas Therapeutics' Price Target to $18 From $21, Keeps Neutral Rating MT
HC Wainwright Initiates Coverage on Calliditas Therapeutics With Buy Rating, $60 Price Target MT
Guggenheim Initiates Calliditas Therapeutics at Neutral With $18 Price Target MT
HC Wainwright Adjusts Calliditas Therapeutics' Price Target to $62 From $52, Reiterates Buy Rating MT
Citigroup Adjusts Calliditas Therapeutics' Price Target to $84 From $51, Reiterates Buy Rating MT
ANALYST RECOMMENDATIONS : Alibaba, Goldman Sachs, Monday.com, Shaftesbury, 3M Company... Our Logo
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
208.2 SEK
Average target price
208 SEK
Spread / Average Target
-0.10%
High Price Target
270 SEK
Spread / Highest target
+29.68%
Low Price Target
161 SEK
Spread / Lowest Target
-22.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Calliditas Therapeutics AB

Citigroup
Stifel Nicolaus
HC Wainwright
Guggenheim

Ratings for Calliditas Therapeutics AB

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. Consensus Calliditas Therapeutics AB